This innovative real-world data study is developing an infrastructure to conduct a study comparing outcomes in patients with EGFR-mutated NSCLC receiving osimertinib with or without chemotherapy and not enrolled in a clinical trial
GI Cancer Committee displays strong representation at ASCO; real-world data study nears activation; ECOG-ACRIN commends NCI's appointment of senior advisor for clinical research
Advanced Practice Providers Working Group debuts soon; community-focused column highlights genetic testing challenges; real-world data efforts accelerate